BOSTON SCIENTIFIC CORP
BSXNYSE · SIC 3841
$44.03
↓ -1.3%Jul 17 close · end-of-day
Price
1Y↓ -57.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$65.8B
Enterprise Value
$75.4B
P/E
18.4
P/S
3.2
P/B
2.5
EV/EBITDA
14.5
PEG
0.3
FCF Yield
5.3%
Dividend Yield
—
Revenue (TTM)
$20.6B
Net Income (TTM)
—
Free Cash Flow (TTM)
$3.5B
Gross Margin
69.2%
Operating Margin
18.4%
Net Margin
—
ROE
—
ROIC
10.2%
Debt / Equity
0.4
Net Cash
-$9.6B
Return 1Y
-57.9%
Company profile
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions.
- CEO
- Michael F. Mahoney
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Employees
- 45,000
- Headquarters
- Massachusetts
- Website
- bostonscientific.com
Management & directors
- Monson JonathanEVP and CFO
- Mahoney Michael FChairman, President & CEO
- Butcher Arthur CEVP& Grp Pres, MedSurg & APAC
- O'Connor Padraig AndrewEVP, Global Operations
- Woodworth EmilySVP, Global Controller and CAO
- Brown Vance REVP, GC and Corp. Secretary
- Fitzgerald Joseph MichaelEVP & Group Pres, Cardiology
- O'Sullivan MiriamSVP, Chief HR Officer
Roles derived from SEC Form 4 filings.
Earnings
Next earnings · estimated2026-07-22
BSX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$5.2B↑ +11.6%
Diluted EPS$0.90↑ +100.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $9.9B | $11.9B | $12.7B | $14.2B | $16.7B | $20.1B |
| Gross profit | $6.4B | $8.2B | $8.7B | $9.9B | $11.5B | $13.9B |
| Operating income | -$80.0M | $1.2B | $1.6B | $2.3B | $2.6B | $3.6B |
| Net income | — | — | — | — | — | — |
| Diluted EPS | -$0.08 | $0.69 | $0.45 | $1.07 | $1.25 | $1.94 |
| Operating cash flow | $1.5B | $1.9B | $1.5B | $2.5B | $3.4B | $4.5B |
| Free cash flow | $1.1B | $1.3B | $938.0M | $1.8B | $2.6B | $3.7B |
| Gross margin | 65.0% | 68.8% | 68.8% | 69.5% | 68.6% | 69.0% |
| Operating margin | -0.8% | 10.1% | 13.0% | 16.5% | 15.5% | 18.0% |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.1B | $4.2B | $4.6B | $4.7B | $5.1B | $5.1B | $5.3B | $5.2B |
| Gross profit | $2.9B | $2.9B | $3.1B | $3.2B | $3.4B | $3.5B | $3.7B | $3.6B |
| Operating income | $520.0M | $733.0M | $675.0M | $921.0M | $819.0M | $1.0B | $825.0M | $1.1B |
| Net income | — | — | — | — | — | — | — | — |
| Diluted EPS | $0.22 | $0.32 | $0.38 | $0.45 | $0.53 | $0.51 | $0.45 | $0.90 |
| Operating cash flow | $813.0M | $1.0B | $1.5B | $541.0M | $1.3B | $1.3B | $1.4B | $348.0M |
| Free cash flow | $658.0M | $823.0M | $1.2B | $354.0M | $1.1B | $1.2B | $1.0B | $171.0M |
| Gross margin | 69.2% | 68.8% | 67.8% | 68.8% | 67.7% | 69.9% | 69.6% | 69.5% |
| Operating margin | 12.6% | 17.4% | 14.8% | 19.8% | 16.2% | 20.7% | 15.6% | 21.2% |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jul 17, 2026
Jul 16, 2026
Jul 15, 2026
- 5d agoBoston Scientific (BSX): Buy, Sell, or Hold Post Q1 Earnings?finance.yahoo.com
- 5d agoBoston Scientific (BSX) Faces WATCHMAN Slowdown But Analysts Still See Upsidefinance.yahoo.com
- 5d agoAre Boston Scientific’s (BSX) Sterile-Packaging Recalls Reframing the Narrative on Quality and Regulatory Risk?finance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-01 | Monson Jonathan· EVP and CFO | Tax withholding | 1,010 | $43.06 | $43,490.60 | filing |
| 2026-07-01 | Monson Jonathan· EVP and CFO | Option exercise | 2,087 | $0.00 | $0.00 | filing |
| 2026-05-28 | Mahoney Michael F· Chairman, President & CEO | Gift | 386,755 | $0.00 | $0.00 | filing |
| 2026-05-20 | LUDWIG EDWARD J | Buy | 3,580 | $56.68 | $202,914.40 | filing |
| 2026-05-20 | Habiger David C | Buy | 2,250 | $55.92 | $125,818.88 | filing |
| 2026-05-20 | Pegus Cheryl | Buy | 1,770 | $56.49 | $99,987.30 | filing |
| 2026-05-19 | Habiger David C | Buy | 2,200 | $56.95 | $125,279.22 | filing |
| 2026-05-07 | Habiger David C | Award | 3,800 | $0.00 | $0.00 | filing |
| 2026-05-07 | LUDWIG EDWARD J | Award | 3,800 | $0.00 | $0.00 | filing |
| 2026-05-07 | Mega Jessica L | Award | 3,800 | $0.00 | $0.00 | filing |
| 2026-05-07 | Zane Ellen M | Award | 3,800 | $0.00 | $0.00 | filing |
| 2026-05-07 | WICHMANN DAVID S | Award | 3,800 | $0.00 | $0.00 | filing |
| 2026-05-07 | Weber Christophe Pierre | Award | 1,767 | $0.00 | $0.00 | filing |
| 2026-05-07 | Weber Christophe Pierre | Award | 1,140 | $0.00 | $0.00 | filing |
| 2026-05-07 | Morano Susan E | Award | 3,800 | $0.00 | $0.00 | filing |
| 2026-05-07 | Morano Susan E | Award | 1,281 | $0.00 | $0.00 | filing |
| 2026-05-02 | Butcher Arthur C· EVP& Grp Pres, MedSurg & APAC | Tax withholding | 1,007 | $56.50 | $56,895.50 | filing |
| 2026-05-02 | O'Connor Padraig Andrew· EVP, Global Operations | Tax withholding | 872 | $56.50 | $49,268.00 | filing |
| 2026-05-02 | O'Connor Padraig Andrew· EVP, Global Operations | Option exercise | 1,802 | $0.00 | $0.00 | filing |
| 2026-05-02 | Butcher Arthur C· EVP& Grp Pres, MedSurg & APAC | Option exercise | 2,102 | $0.00 | $0.00 | filing |
| 2026-03-02 | Weber Christophe Pierre | Award | 556 | $0.00 | $0.00 | filing |
| 2026-03-02 | Morano Susan E | Award | 24 | $0.00 | $0.00 | filing |
| 2026-03-02 | Weber Christophe Pierre | Award | 323 | $0.00 | $0.00 | filing |
| 2026-03-01 | Woodworth Emily· SVP, Global Controller and CAO | Tax withholding | 372 | $76.85 | $28,588.20 | filing |
| 2026-03-01 | Woodworth Emily· SVP, Global Controller and CAO | Option exercise | 838 | $0.00 | $0.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.